Nugen looks back at 2025 R&D programs

Executive Summary

• Nugen Medical Devices Inc. released a comprehensive 2025 year-end update detailing significant advancements in its research and development pipeline, technical infrastructure, and global commercial activities.
• The company highlighted key product developments, including the feasibility demonstration of a ready-to-fill nozzle for prefilled drug formats, advancements in next-generation variable-dose jet injectors, and progress on a patented refill system for direct cartridge storage.
• Commercial milestones include the launch of the Eziautojector private label device in the UK with NHS drug tariff approval, alongside expanded clinical teams and distributor engagements in France, Brazil, Malaysia, Mexico, Asia, and Canada.

Key Details

• R&D Product Developments:
  • Demonstrated feasibility of a ready-to-fill nozzle for sterile, ready-to-use pharmaceutical filling systems to support prefilled drug formats.
  • Advanced next-generation variable-dose jet injector to align with clinical practice and reduce training requirements.
  • Initiated pressure-profile optimization to improve injection comfort and consistency.
  • Progressed prototypes for a patented refill system designed for direct cartridge storage.
  • Advanced an animal-use injector for release under the PetJet brand.
• Technical and Engineering Expansion:
  • Expanded the Netherlands design hub with new roles focused on pharma-focused device development.
  • Added two medtech specialists in China to strengthen testing, validation, and cost-effective development execution.
• Clinical and Medical Engagement:
  • Expanded clinical teams in France, Brazil, and Malaysia to support real-world evidence generation, local evaluations, and patient experience initiatives.
  • Initiated the formation of a medical advisory board to guide product relevance and clinical alignment.
• Commercial and Market Activity:
  • United Kingdom: Launched the Eziautojector private label device and secured NHS drug tariff approval.
  • Global Markets: Continued distributor engagement, clinician feedback collection, and insurance coverage discussions in Mexico, Asia, and Canada.
  • Events: Supporting Sol Millennium Medical Group's participation at Pharmapack Europe 2026 to highlight Nugen's needle-free technology.

Notable Quotes

• "Our progress in 2025 reflects the disciplined work of our teams across R&D, clinical development, and global market engagement. The advancements made this year strengthen our foundation and support the continued evolution of our needle-free technology." — Liang Lin, Chief Executive Officer